Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]Tc-TECANT1
- Development stage
- Phase 1
- Lead developer
- National Centre for Nuclear Research
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
[99mTc]Tc-TECANT1 is a radiopharmaceutical agent consisting of the somatostatin receptor subtype 2 (SST2) antagonist peptide TECANT-1 labeled with technetium-99m. It is developed for single-photon emission computed tomography (SPECT) imaging of neuroendocrine tumors (NETs), leveraging the high expression of SST2 on these tumors. As an antagonist, it binds to SST2 receptors on tumor cells but does not activate them, allowing for improved tumor targeting and diagnostic sensitivity compared to agonists. The drug is formulated as a freeze-dried kit for hospital radiopharmacy preparation and has demonstrated favorable preclinical safety and stability profiles. Clinical development has reached early phase 1 trials in Europe[1][3][4][6].
- Other names
- 99mTc-TECANT199mTc-labeled SSTR2-Antagonist
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on [99mTc]Tc-TECANT1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [99mTc]Tc-TECANT1.